At Drug Discovery 2026 in Burlingame, California, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (https://ibn.ai/clients/oncotelic-therapeutics-inc/) outlined a development strategy that integrates biomedical literature analysis with therapeutic development. Scott Myers, Product Manager, and Saran Saund, Chief Business Officer, presented the company’s PDAOAI discovery platform and a case study in hepatocellular carcinoma (HCC).
On October 7, Myers presented “The Infinity Problem: AI Search Aggregation for Biomedical Knowledge Discovery in Drug Development.” He described how PDAOAI searches and organizes an index of approximately 29 million PubMed abstracts to support focused biomedical research. The platform is designed to help researchers navigate the overwhelming volume of scientific literature and identify relevant evidence for hypothesis generation.
On October 8, Saund followed with an HCC case study describing how disease-specific literature analysis led to a four-gene mTOR-related signature associated with survival in an exploratory discovery analysis and an independent Japanese cohort. The findings suggest that AI-driven literature analysis can surface potential biomarkers and therapeutic targets for further investigation. The full presentation is available in the company’s SEC filing (https://www.sec.gov/Archives/edgar/data/908259/000149315226046751/ex99-1.htm).
The presentations highlight how Oncotelic is leveraging artificial intelligence to connect vast scientific knowledge with practical drug development. By systematically mining the biomedical literature, PDAOAI aims to uncover relationships and patterns that might otherwise remain hidden, potentially accelerating the identification of new drug candidates and biomarkers. The HCC signature, derived from such analysis, exemplifies this approach and underscores the potential of AI to inform precision medicine strategies.
Oncotelic’s participation in Drug Discovery 2026 also included an announcement about BIO REBOOT, an initiative that connects the platform’s research capabilities with potential funding and development support for selected projects. This initiative could help bridge the gap between computational discoveries and the resources needed to advance them toward clinical application. More details are available in the company’s newsroom (ibn.fm/OTLC).
The company’s work reflects a broader trend in the pharmaceutical industry, where AI and machine learning are increasingly used to analyze large datasets and generate hypotheses. If validated, such approaches could reduce the time and cost of early-stage drug discovery. Oncotelic’s focus on mTOR-related pathways in HCC aligns with ongoing efforts to develop targeted therapies for liver cancer, a disease with significant unmet need.
The presentations were distributed via InvestorWire (InvestorWire), a specialized communications platform that is part of the Dynamic Brand Portfolio (Dynamic Brand Portfolio) at IBN (IBN). The platform offers editorial syndication to 5,000+ outlets (editorial syndication to 5,000+ outlets), press release enhancement (press release enhancement), and social media distribution (social media distribution), among other corporate communications solutions (corporate communications solutions).
For investors, the event provides insight into Oncotelic’s technological capabilities and its strategy to position itself at the intersection of AI and drug development. While the HCC signature is exploratory, it demonstrates the platform’s potential to generate actionable hypotheses. As the company advances its pipeline, the ability to efficiently mine and synthesize scientific literature could become a competitive advantage.
